Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Michael J. Broman, Emily Pasman, Suzanne Brown, Jamey J. Lister, Elizabeth Agius & Stella M. Resko. (2023) Social support is associated with reduced stigma and shame in a sample of rural and small urban adults in methadone treatment. Addiction Research & Theory 31:1, pages 37-44.
Read now
Read now
A. Taylor Kelley, Michael A. Incze, Jacob D. Baylis, Spencer G. Calder, Saul J. Weiner, Susan L. Zickmund, Audrey L. Jones, Megan E. Vanneman, Molly B. Conroy, Adam J. Gordon & John F.P. Bridges. (2022) Patient-centered quality measurement for opioid use disorder: Development of a taxonomy to address gaps in research and practice. Substance Abuse 43:1, pages 1286-1299.
Read now
Read now
Chin Hwa (Gina) Dahlem, Marci Scalera, Glynis Anderson, Melisa Tasker, Robert Ploutz-Snyder, Sean Esteban McCabe & Carol J. Boyd. (2021) Recovery opioid overdose team (ROOT) pilot program evaluation: A community-wide post-overdose response strategy. Substance Abuse 42:4, pages 423-427.
Read now
Read now
Virgil Lee Gregory$suffix/text()$suffix/text() & Rebecca J. Bartlett Ellis. (2020) Cognitive-behavioral therapy and buprenorphine for opioid use disorder: A systematic review and meta-analysis of randomized controlled trials. The American Journal of Drug and Alcohol Abuse 46:5, pages 520-530.
Read now
Read now
Bennett Allen, Michelle L. Nolan & Denise Paone. (2019) Underutilization of medications to treat opioid use disorder: What role does stigma play?. Substance Abuse 40:4, pages 459-465.
Read now
Read now
Ditte Andersen & Malene Lue Kessing. (2019) Stigma, problem drug use, and welfare state encounters: changing contours of stigmatization in the era of social investment. Addiction Research & Theory 27:4, pages 277-284.
Read now
Read now
Articles from other publishers (23)
Arturo Soto‐Nevarez, Mary Abo, Mackenzie Hudson, Ted Bobak & Leonard A. Jason. (2023) Lived experiences of Oxford House residents prescribed medication‐assisted treatment. Journal of Community Psychology 51:7, pages 2828-2844.
Crossref
Crossref
Mahnaz Zali, Azad Rahmani, Kelly Powers, Hadi Hassankhani, Hossein Namdar-Areshtanab & Neda Gilani. (2022) Nurses’ experiences of ethical and legal issues in post-resuscitation care: A qualitative content analysis. Nursing Ethics 30:2, pages 245-257.
Crossref
Crossref
Alexis Carl, Emily Pasman, Michael J. Broman, Jamey J. Lister, Elizabeth Agius & Stella M. Resko. (2023) Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug and Alcohol Dependence Reports 6, pages 100138.
Crossref
Crossref
Erin F. Madden, Kristin K. Barker, Joshua Guerra, Corey Villanueva & Sandra H. Sulzer. (2022) Variation in intervention stigma among medications for opioid use disorder. SSM - Qualitative Research in Health 2, pages 100161.
Crossref
Crossref
Salomon Poliwoda, Nazir Noor, Jack S. Jenkins, Cain W. Stark, Mattie Steib, Jamal Hasoon, Giustino Varrassi, Ivan Urits, Omar Viswanath, Adam M. Kaye & Alan D Kaye. (2022) Buprenorphine and its formulations: a comprehensive review. Health Psychology Research 10:3.
Crossref
Crossref
Yi-Ping Hsieh, Yun-Ju Wang, Ling-Yi Feng, Li-Tzy Wu & Jih-Heng Li. (2022) Mifepristone (RU-486®) as a Schedule IV Controlled Drug—Implications for a Misleading Drug Policy on Women’s Health Care. International Journal of Environmental Research and Public Health 19:14, pages 8363.
Crossref
Crossref
Benjamin Lai, Ivana Croghan & Jon O. Ebbert. (2022) Buprenorphine Waiver Attitudes Among Primary Care Providers. Journal of Primary Care & Community Health 13, pages 215013192211122.
Crossref
Crossref
Karen Werder, Alexa Curtis, Stephanie Reynolds & Jason Satterfield. (2021) Addressing Bias and Stigma in the Language We Use With Persons With Opioid Use Disorder: A Narrative Review. Journal of the American Psychiatric Nurses Association 28:1, pages 9-22.
Crossref
Crossref
J. Janet HoKatie F. JonesZachary SagerSarah WakemanJessica S. Merlin. (2022) De-Stigmatizing the Language of Addiction #429. Journal of Palliative Medicine 25:1, pages 155-157.
Crossref
Crossref
Natalie M. Brousseau, Heather Farmer, Allison Karpyn, Jean-Philippe Laurenceau, John F. Kelly, Elizabeth C. Hill & Valerie A. Earnshaw. (2022) Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences. Journal of Substance Abuse Treatment 132, pages 108593.
Crossref
Crossref
August F. Holtyn, Forrest Toegel, Matthew D. Novak & Kenneth Silverman. (2021) Factors associated with obtaining employment among opioid use disorder patients enrolled in a therapeutic workplace intervention. Drug and Alcohol Dependence 226, pages 108907.
Crossref
Crossref
Max Weiss & Michael Zoorob. (2021) Political frames of public health crises: Discussing the opioid epidemic in the US Congress. Social Science & Medicine 281, pages 114087.
Crossref
Crossref
Jordan M. Hyatt & Philipp P. Lobmaier. (2020) Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation. Health & Justice 8:1.
Crossref
Crossref
Emma L. Richard, Christine A. Schalkoff, Hannah M. Piscalko, Daniel L. Brook, Adams L. Sibley, Kathryn E. Lancaster, William C. Miller & Vivian F. Go. (2020) “You are not clean until you're not on anything”: Perceptions of medication-assisted treatment in rural Appalachia. International Journal of Drug Policy 85, pages 102704.
Crossref
Crossref
Elizabeth A. Hall, Alina Cernasev, Umida Nasritdinova, Michael P. Veve & Kenneth C. Hohmeier. (2020) Stigma of Opioid Use Disorder and Its Indirect Effects on Student Pharmacists’ Perceptions and Attitudes. Pharmacy 8:3, pages 144.
Crossref
Crossref
Hillary V. Kunins. (2020) Structural Racism and the Opioid Overdose Epidemic: The Need for Antiracist Public Health Practice. Journal of Public Health Management and Practice 26:3, pages 201-205.
Crossref
Crossref
Robert E. Davis, Nicole A. Doyle & Vinayak K. Nahar. (2020) Association between prescription opioid misuse and dimensions of suicidality among college students. Psychiatry Research 287, pages 112469.
Crossref
Crossref
Erin Fanning Madden. (2019) Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Social Science & Medicine 232, pages 324-331.
Crossref
Crossref
Lydia Anne M. Bartholow & Justine Pope. (2018) Use of Buprenorphine to Treat Opioid Use Disorder. Journal of Psychosocial Nursing and Mental Health Services 56:11, pages 9-12.
Crossref
Crossref
Kamilla L. Venner, Dennis M. Donovan, Aimee N.C. Campbell, Dennis C. Wendt, Traci Rieckmann, Sandra M. Radin, Sandra L. Momper & Carmen L. Rosa. (2018) Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives. Addictive Behaviors 86, pages 111-117.
Crossref
Crossref
Michelle R. Lofwall, Sharon L. Walsh, Edward V. Nunes, Genie L. Bailey, Stacey C. Sigmon, Kyle M. Kampman, Michael Frost, Fredrik Tiberg, Margareta Linden, Behshad Sheldon, Sonia Oosman, Stefan Peterson, Michael Chen & Sonnie Kim. (2018) Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder. JAMA Internal Medicine 178:6, pages 764.
Crossref
Crossref
Erin M. Kerrison. (2018) Exploring how prison-based drug rehabilitation programming shapes racial disparities in substance use disorder recovery. Social Science & Medicine 199, pages 140-147.
Crossref
Crossref
Sasha Cooper & Suzanne Nielsen. (2016) Stigma and Social Support in Pharmaceutical Opioid Treatment Populations: a Scoping Review. International Journal of Mental Health and Addiction 15:2, pages 452-469.
Crossref
Crossref